Sydney - Thursday - August 28: (RWE Australian Business News) - Progen Pharmaceuticals (ASX:PGL) reports a strong cash balance of $76.7m and net tangible assets of $1.19 per share. The consolidated loss for the year totalled $26.1m (2007: $22.5m) on operating revenues of $7.8m (2007: $3.8m). The loss was impacted by a $3.8m unrealised foreign currency charge due to the Company holding significant USD cash and cash equivalents and $4.0m being expensed in relation to the unwind of the Medigen strategic alliance.
PGL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held